PharmTech Drug Digest 11.20
News|Articles|February 12, 2020

Vectura Appoints Sharon Johnson Executive VP

Inhalation drug delivery company Vectura announces new organizational structure to drive innovation, customer focus, and growth.

Vectura Group plc, a United Kingdom-based provider of inhaled drug delivery services, has named Sharon Johnson as executive vice-president for delivery management. In this newly created role, Johnson will focus on helping customer acquisition, program management, and regulatory medical affairs, the company reported in a Feb. 10, 2020 announcement.

Johnson has more than 30 years of experience in the pharmaceutical industry, including previous positions at Catalent, GE Healthcare’s Medical Diagnostic Division, Baxter Healthcare, and Sanofi Aventis. She holds a postgraduate diploma in industrial pharmaceutical studies with distinction from Brighton University and a bachelor’s Honors degree in biological sciences/microbiology from North East Surrey College of

“Sharon has built an enviable reputation as an exceptional leader in the pharmaceutical services space and has a strong track record of transformational leadership, talent development, and execution excellence,” said Will Downie, Vectura CEO, in the press statement. “Our new structure will support growth and sharpen our focus on working with our clients to bring more inhalation medicines to market.”

 “Having spent my entire career in the healthcare arena, it is a true privilege to join Vectura, a company with such a rich scientific heritage in the inhalation space,” said Johnson in the press statement. “I look forward to working with my colleagues on the executive leadership team and wider business to help combine deep science and agile processes that will accelerate the development of new and exciting inhaled medicines for patients.”

Source: Vectura

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.